Table 1 Characteristics of the study population
| Â | Entire group (n=80)* | Patients treated with raltegravir (n=46) |
|---|---|---|
Female gender, n (%) | 34 (42.5) | 19 (41.3) |
Transmission route | ||
IDU, n (%) | 19 (23.8) | 13 (28.3) |
Heterosexual, n (%) | 43 (53.8) | 22 (47.8) |
MSM, n (%) | 17 (21.3) | 10 (21.7) |
Unknown, n (%) | 1 (1.3) | 1 (2.2) |
CDC category at HIV diagnosis | ||
A , n (%) | 23 (28.8) | 14 (30.4) |
B, n (%) | 34 (42.5) | 19 (41.3) |
C, n (%) | 22 (27.5) | 14 (30.4) |
Lymphocyte CD4 count at diagnosis, median cells/μl, (IQR) | 147 (51-331) | 140 (29-336) |
Lymphocyte CD4 count prior to raltegravir introduction, median cells/μl (IQR) | N.A. | 335 (154-515) |
HIV viral load at diagnosis, median log HIV-1 copies/ml (IQR) | 5.33 ( 4.62-5.88) | 5.38 |
(4.62-5.56) | ||
HIV-RNA undetectable prior to raltegravir introduction, n (%) | N.A. | 20 (44) |
HIV viral load prior to raltegravir introduction, median log HIV-1 copies/ml (IQR) | N.A. | 4.88 (3.36-5.44) |
HIV-1 subtype (integrase coding region) * | ||
B, n (%) | 48 (61.5) | 30 (68.2) |
D , n (%) | 24 (30.8) | 10 (21.7) |
C, n (%) | 2 (2.6) | 2 (4.5) |
G, n (%) | 1 (1.3) | 0 |
CRF01_AE , n (%) | 1 (1.3) | 1 (2.3) |
CRF02_AG, n (%) | 1 (1.3) | 1 (2.3) |
CRF13_cpx , n (%) | 1 (1.3) | 0 |
Baseline integrase polymorphisms * | ||
None , n (%) | 48 (61.5) | 24 (54.5) |
E157Q , n (%) | 23 (28.8) | 15 (34.1) |
V151I, n (%) | 2 (3.1) | 1 (2.3) |
E138D, n (%) | 2 (2.6) | 0 |
T97A, n (%) | 1 (1.3) | 1 (2.3) |
R263K, n (%) | 1 (1.3) | 1 (2.3) |
L74IL, n (%) | 1 (1.3) | 1 (2.3) |
L68V, n (%) | 1 (1.3) | 1 (2.3) |